Doaa Sobeih1, Khaled A Hussein1, Neveen Said2, Kouros Motamed3, Mohamed Al-Shabrawey4. 1. Oral Biology/Anatomy, College of Dental Medicine, Georgia Regents University (GRU), Augusta, GA, USA ; James & Jean Culver Vision Discovery Institute, GRU, USA ; Ophthalmology, Medical College of Georgia (MCG), GRU, USA. 2. Department of Radiation Oncology, University of Virginia School of Medicine, USA. 3. Igdrasol, Irivin, CA, USA. 4. Oral Biology/Anatomy, College of Dental Medicine, Georgia Regents University (GRU), Augusta, GA, USA ; James & Jean Culver Vision Discovery Institute, GRU, USA ; Ophthalmology, Medical College of Georgia (MCG), GRU, USA ; Cellular Biology and Anatomy, MCG, GRU, USA.
Abstract
BACKGROUND: Secreted Protein Acidic and Rich in Cysteine (SPARC) is a matricellular protein which is implicated in regulation of angiogenesis. PURPOSE: To characterize the changes in SPARC expression and effect of its deletion in a mouse model Oxygen Induced Retinopathy (OIR). MATERIALS AND METHODS: Wild type (wt) and SPARC-deficient mice were subjected to high oxygen (75%) for 5 days (p7-p12) before room air for additional 5 days (p12-p17). Retinas from both groups were flat mounted and retinal vessels were labeled with Isolectin-B4. Areas of Retinal Neovascularization (RNV) and vaso-obliteration were measured by Image-J and normalized to total retinal areas. SPARC expression was analyzed in both groups at p14 and p17 in retinal homogenates and sections by Western Blotting (WB) and immunofluorescence respectively. Human Retinal Endothelial Cells (HRECs) were exposed to hypoxia (1% O2) for 6 hours then SPARC was measured in cell lysate and condition medium by WB and ELISA. Moreover, HRECs were treated with VEGF or SPARC to study their mutual regulatory effect. RESULTS: SPARC-deficient mice demonstrated significant increase in the vaso-obliteration (p=0.03) and modest increase in RNV compared to the wt control. Retinal levels of SPARC was significantly decreased during OIR at p14 (p=0.01) and partially restored to normal level by p17. Moreover, hypoxia significantly reduced SPARC expression and secretion in HRECs (p=0.001). We noticed a mutual positive regulatory feedback between SPARC and VEGF. CONCLUSION: SPARC deletion enhances ischemic retinopathy, thus modulation of SPARC expression could be a novel therapeutic approach to prevent pathological RNV.
BACKGROUND:Secreted Protein Acidic and Rich in Cysteine (SPARC) is a matricellular protein which is implicated in regulation of angiogenesis. PURPOSE: To characterize the changes in SPARC expression and effect of its deletion in a mouse model Oxygen Induced Retinopathy (OIR). MATERIALS AND METHODS: Wild type (wt) and SPARC-deficient mice were subjected to high oxygen (75%) for 5 days (p7-p12) before room air for additional 5 days (p12-p17). Retinas from both groups were flat mounted and retinal vessels were labeled with Isolectin-B4. Areas of Retinal Neovascularization (RNV) and vaso-obliteration were measured by Image-J and normalized to total retinal areas. SPARC expression was analyzed in both groups at p14 and p17 in retinal homogenates and sections by Western Blotting (WB) and immunofluorescence respectively. Human Retinal Endothelial Cells (HRECs) were exposed to hypoxia (1% O2) for 6 hours then SPARC was measured in cell lysate and condition medium by WB and ELISA. Moreover, HRECs were treated with VEGF or SPARC to study their mutual regulatory effect. RESULTS:SPARC-deficient mice demonstrated significant increase in the vaso-obliteration (p=0.03) and modest increase in RNV compared to the wt control. Retinal levels of SPARC was significantly decreased during OIR at p14 (p=0.01) and partially restored to normal level by p17. Moreover, hypoxia significantly reduced SPARC expression and secretion in HRECs (p=0.001). We noticed a mutual positive regulatory feedback between SPARC and VEGF. CONCLUSION:SPARC deletion enhances ischemic retinopathy, thus modulation of SPARC expression could be a novel therapeutic approach to prevent pathological RNV.
Authors: Mohamed Al-Shabrawey; Manuela Bartoli; Azza B El-Remessy; Daniel H Platt; Sue Matragoon; M Ali Behzadian; Robert W Caldwell; Ruth B Caldwell Journal: Am J Pathol Date: 2005-08 Impact factor: 4.307
Authors: Lawrence A Yannuzzi; Silvana Negrão; Tomohiro Iida; Cynthia Carvalho; Hanna Rodriguez-Coleman; Jason Slakter; K Bailey Freund; John Sorenson; Dennis Orlock; Natalie Borodoker Journal: Retina Date: 2012-02 Impact factor: 4.256
Authors: L E Smith; E Wesolowski; A McLellan; S K Kostyk; R D'Amato; R Sullivan; P A D'Amore Journal: Invest Ophthalmol Vis Sci Date: 1994-01 Impact factor: 4.799
Authors: Virginia Haurigot; Pilar Villacampa; Albert Ribera; Assumpcio Bosch; David Ramos; Jesus Ruberte; Fatima Bosch Journal: PLoS One Date: 2012-07-20 Impact factor: 3.240
Authors: Christopher K Yunker; William Golembieski; Nancy Lemke; Chad R Schultz; Simona Cazacu; Chaya Brodie; Sandra A Rempel Journal: Int J Cancer Date: 2008-06-15 Impact factor: 7.396
Authors: Stefaniya Konstantinova Boneva; Julian Wolf; Rozina Ida Hajdú; Gabriele Prinz; Henrike Salié; Anja Schlecht; Saskia Killmer; Yannik Laich; Henrik Faatz; Albrecht Lommatzsch; Martin Busch; Felicitas Bucher; Andreas Stahl; Daniel Böhringer; Bertram Bengsch; Günther Schlunck; Hansjürgen Agostini; Clemens A K Lange Journal: Front Immunol Date: 2021-11-02 Impact factor: 7.561